FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213012313> ?p ?o ?g. }

• W3213012313 endingPage "1748" @default.
• W3213012313 startingPage "1748" @default.
• W3213012313 abstract "Abstract Introduction Although the labeled CD19 targeting CAR-T cell constructs axi-cel and tisa-cel are generally associated with an acceptable safety profile, non-relapse deaths can occur. Little is known about timing, causes and predictors of NRM following SOC CAR-T cell therapy for LBCL. Here, we analyzed frequency, causes, and risk factors of non-relapse deaths with focus on late NRM (beyond 4 weeks after dosing) using registry data provided by the DRST, the national partner of the EBMT. Methods Patients were selected from 356 consecutive patients who received SOC CAR-T treatment of LBCL between November 2018 and April 2021 at 21 German centers and were registered with the DRST/EBMT. Baseline patient, disease, and transplant data were collected from MED-A cellular therapy forms. Centers were contacted to provide additional treatment and follow-up information. Patients with late NRM (defined as NRM occurring beyond 4 weeks after dosing without prior LBCL relapse or progression) were compared with all patients surviving progression-free the 4-week landmark after dosing without subsequent NRM. Cumulative incidences of NRM were calculated considering relapse/progression as competing event. Results The analysis set consisted of 312 patients surviving progression-free at least 28 days after CAR-T treatment and remained alive until the end of follow-up or had a documented cause of death. Median age was 61 years (19-83), 66% were male, 52% had an IPI ≥3, 13 had an ECOG score &gt;1, 70% had received ≥3 treatment lines, 33% had failed a prior HCT, and 78% were refractory at lymphodepletion. 50% had been treated at a center contributing ≥20 cases with axi-cel (52%) or tisa-cel (48%). Grade ≥3 CRS and grade ≥3 neurotoxicity (NT) had occurred in 11% each, and 7% had no neutrophil recovery at day 100 post dosing or at last follow-up, whatever was earlier. With a median follow-up of 11.2 months, 124 patients (40%) had died, 109 (35%) LBCL-related, and 15 (5%) because of NRM. The cumulative incidence of late NRM at 12 months post dosing was 4.3% (95%CI 2.0-6.6). Causes of NRM were infections in 10 patients (bacterial or fungal sepsis/pneumonia 6; viral/atypical pneumonia/encephalitis 4); late NT 2; hyperinflammatory syndrome 1; 2 nd malignancy 1; unknown 1). Of note, 5 of the 6 lethal fungal/bacterial infections occurred subsequent to high grade NT. There was no significant difference between patients experiencing and not experiencing NRM in terms of age, gender, IPI, ECOG, pretreatment lines, prior HCT, disease status at lymphodepletion, and grade ≥3 CRS frequency. However, a significantly larger proportion of patients with late NRM had failed neutrophil recovery (27% vs 5%, p 0.011), had experienced grade ≥3 NT (40% vs 10%, p 0.0031), and/or had received axi-cel (93% vs 51%, p 0.001). Patients having neutrophil non-recovery and/or grade ≥3 NT had a 12-month NRM incidence of 16% (95%CI 5.1-26.9) vs 2.5% (95%CI 0.3-4.7) in patients with none of these 2 factors. Conclusions Late NRM in patients receiving SOC CAR-T treatment for LBCL is largely driven by infections. Risk factors for late NRM appear to be protracted neutropenia and higher grade NT, suggesting that intensified anti-bacterial/anti-fungal prophylaxis may be considered in patients with persisting critical neutropenia or exposed to high-dose steroids for NT treatment. Figure 1 Figure 1. Disclosures Dreger: BMS: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Bluebird Bio: Consultancy; AbbVie: Consultancy, Speakers Bureau; Gilead Sciences: Consultancy, Speakers Bureau; Janssen: Consultancy; Novartis: Consultancy, Speakers Bureau; Riemser: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau. Schubert: Gilead: Consultancy. Holtick: Sanofi: Honoraria; Celgene: Honoraria. Subklewe: Miltenyi: Research Funding; Takeda: Speakers Bureau; Gilead: Consultancy, Research Funding, Speakers Bureau; Klinikum der Universität München: Current Employment; MorphoSys: Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Roche: Research Funding; Seattle Genetics: Consultancy, Research Funding; Pfizer: Consultancy, Speakers Bureau; Janssen: Consultancy; BMS/Celgene: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau. Bastian: Abbvie: Other; Amgen: Consultancy, Honoraria; Astra Zeneca: Honoraria, Other; BMS and Celgene: Consultancy, Honoraria, Other; Kite-Gilead: Consultancy, Honoraria; MSD: Consultancy, Honoraria, Other, Research Funding; Novartis: Consultancy, Honoraria, Other, Research Funding; Pentixafarm: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other, Research Funding. Ayuk: Gilead: Honoraria; Celgene/BMS: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Miltenyi Biomedicine: Honoraria; Mallinckrodt/Therakos: Honoraria, Research Funding; Novartis: Honoraria. Marks: Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Honoraria; Merck: Consultancy; AbbVie: Other: Meeting attendance. Penack: Priothera: Consultancy; Takeda: Research Funding; Incyte: Research Funding; Neovii: Honoraria; Pfizer: Honoraria; Therakos: Honoraria; Novartis: Honoraria; MSD: Honoraria; Jazz: Honoraria; Gilead: Honoraria; Astellas: Honoraria; Shionogi: Consultancy; Omeros: Consultancy. Koenecke: EUSA Pharm: Consultancy; Kite/Gilead: Consultancy; BMS/Celgene: Consultancy; Janssen: Consultancy; Novartis: Consultancy. Von Bonin: Daiichi Sankyo: Other: traveling support and advisory fees; Novartis: Other: traveling support and advisory fees; Kite/Gilead: Other: traveling support and advisory fees. Stelljes: Novartis: Consultancy, Speakers Bureau; MSD: Consultancy, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Medac: Speakers Bureau; Celgene/BMS: Consultancy, Speakers Bureau; Kite/Gilead: Consultancy, Speakers Bureau. Glass: BMS: Consultancy; Helios Klinik Berlin-Buch: Current Employment; Kite: Consultancy; Novartis: Consultancy; Riemser: Research Funding; Roche: Consultancy, Research Funding, Speakers Bureau. Baldus: Novartis: Honoraria; Amgen: Honoraria; Celgene/BMS: Honoraria; Jazz: Honoraria. Vucinic: MSD: Honoraria; Novartis: Honoraria; Gilead: Honoraria, Other: Travel Sponsoring; Janssen: Honoraria, Other: Travel Sponsoring; Abbvie: Honoraria, Other: Travel Sponsoring. Topp: Universitatklinikum Wurzburg: Current Employment; Celgene: Consultancy, Research Funding; Janssen: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Novartis: Consultancy; Roche: Consultancy, Research Funding; Gilead: Research Funding; Regeneron: Consultancy, Research Funding; Macrogeniecs: Research Funding; Amgen: Consultancy, Research Funding. Schroers: BMS/Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Takeda: Honoraria. Hanoun: AstraZeneca: Honoraria; Abbvie: Other: travel expenses; Novartis: Research Funding. Thomas: AbbVie: Honoraria, Speakers Bureau; Art tempi: Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Other, Research Funding, Speakers Bureau; EUSA Pharma: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other; Kite/Gilead: Honoraria, Other, Research Funding, Speakers Bureau; Medigene: Consultancy, Honoraria, Other; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other; Pfizer: Consultancy, Honoraria, Other, Speakers Bureau. Kröger: Novartis: Research Funding; Riemser: Honoraria, Research Funding; Sanofi: Honoraria; Neovii: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Gilead/Kite: Honoraria; Celgene: Honoraria, Research Funding; AOP Pharma: Honoraria. Bethge: Novartis: Consultancy, Honoraria, Speakers Bureau; Miltenyi Biotec: Consultancy, Honoraria, Research Funding, Speakers Bureau; Kite-Gilead: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau." @default.
• W3213012313 created "2021-11-22" @default.
• W3213012313 creator A5001646221 @default.
• W3213012313 creator A5002261556 @default.
• W3213012313 creator A5006288618 @default.
• W3213012313 creator A5006388833 @default.
• W3213012313 creator A5008074390 @default.
• W3213012313 creator A5011903306 @default.
• W3213012313 creator A5017565182 @default.
• W3213012313 creator A5020116063 @default.
• W3213012313 creator A5021887070 @default.
• W3213012313 creator A5021974658 @default.
• W3213012313 creator A5023183268 @default.
• W3213012313 creator A5027335873 @default.
• W3213012313 creator A5029448872 @default.
• W3213012313 creator A5035426042 @default.
• W3213012313 creator A5036689502 @default.
• W3213012313 creator A5036872888 @default.
• W3213012313 creator A5039235274 @default.
• W3213012313 creator A5040594919 @default.
• W3213012313 creator A5041262204 @default.
• W3213012313 creator A5047314357 @default.
• W3213012313 creator A5054210888 @default.
• W3213012313 creator A5064132655 @default.
• W3213012313 creator A5069131872 @default.
• W3213012313 creator A5071753657 @default.
• W3213012313 creator A5079198423 @default.
• W3213012313 creator A5083461984 @default.
• W3213012313 creator A5084494517 @default.
• W3213012313 creator A5085146093 @default.
• W3213012313 creator A5088208446 @default.
• W3213012313 date "2021-11-05" @default.
• W3213012313 modified "2023-10-12" @default.
• W3213012313 title "Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis" @default.
• W3213012313 doi "https://doi.org/10.1182/blood-2021-151469" @default.
• W3213012313 hasPublicationYear "2021" @default.
• W3213012313 type Work @default.
• W3213012313 sameAs 3213012313 @default.
• W3213012313 citedByCount "0" @default.
• W3213012313 crossrefType "journal-article" @default.
• W3213012313 hasAuthorship W3213012313A5001646221 @default.
• W3213012313 hasAuthorship W3213012313A5002261556 @default.
• W3213012313 hasAuthorship W3213012313A5006288618 @default.
• W3213012313 hasAuthorship W3213012313A5006388833 @default.
• W3213012313 hasAuthorship W3213012313A5008074390 @default.
• W3213012313 hasAuthorship W3213012313A5011903306 @default.
• W3213012313 hasAuthorship W3213012313A5017565182 @default.
• W3213012313 hasAuthorship W3213012313A5020116063 @default.
• W3213012313 hasAuthorship W3213012313A5021887070 @default.
• W3213012313 hasAuthorship W3213012313A5021974658 @default.
• W3213012313 hasAuthorship W3213012313A5023183268 @default.
• W3213012313 hasAuthorship W3213012313A5027335873 @default.
• W3213012313 hasAuthorship W3213012313A5029448872 @default.
• W3213012313 hasAuthorship W3213012313A5035426042 @default.
• W3213012313 hasAuthorship W3213012313A5036689502 @default.
• W3213012313 hasAuthorship W3213012313A5036872888 @default.
• W3213012313 hasAuthorship W3213012313A5039235274 @default.
• W3213012313 hasAuthorship W3213012313A5040594919 @default.
• W3213012313 hasAuthorship W3213012313A5041262204 @default.
• W3213012313 hasAuthorship W3213012313A5047314357 @default.
• W3213012313 hasAuthorship W3213012313A5054210888 @default.
• W3213012313 hasAuthorship W3213012313A5064132655 @default.
• W3213012313 hasAuthorship W3213012313A5069131872 @default.
• W3213012313 hasAuthorship W3213012313A5071753657 @default.
• W3213012313 hasAuthorship W3213012313A5079198423 @default.
• W3213012313 hasAuthorship W3213012313A5083461984 @default.
• W3213012313 hasAuthorship W3213012313A5084494517 @default.
• W3213012313 hasAuthorship W3213012313A5085146093 @default.
• W3213012313 hasAuthorship W3213012313A5088208446 @default.
• W3213012313 hasBestOaLocation W32130123131 @default.
• W3213012313 hasConcept C126322002 @default.
• W3213012313 hasConcept C143998085 @default.
• W3213012313 hasConcept C2777257650 @default.
• W3213012313 hasConcept C2779338263 @default.
• W3213012313 hasConcept C71924100 @default.
• W3213012313 hasConceptScore W3213012313C126322002 @default.
• W3213012313 hasConceptScore W3213012313C143998085 @default.
• W3213012313 hasConceptScore W3213012313C2777257650 @default.
• W3213012313 hasConceptScore W3213012313C2779338263 @default.
• W3213012313 hasConceptScore W3213012313C71924100 @default.
• W3213012313 hasIssue "Supplement 1" @default.
• W3213012313 hasLocation W32130123131 @default.
• W3213012313 hasOpenAccess W3213012313 @default.
• W3213012313 hasPrimaryLocation W32130123131 @default.
• W3213012313 hasRelatedWork W156606841 @default.
• W3213012313 hasRelatedWork W1958784597 @default.
• W3213012313 hasRelatedWork W2002884974 @default.
• W3213012313 hasRelatedWork W2005056863 @default.
• W3213012313 hasRelatedWork W2028125597 @default.
• W3213012313 hasRelatedWork W2077676099 @default.
• W3213012313 hasRelatedWork W2125323275 @default.
• W3213012313 hasRelatedWork W2897496508 @default.
• W3213012313 hasRelatedWork W2898408635 @default.
• W3213012313 hasRelatedWork W3034625857 @default.
• W3213012313 hasVolume "138" @default.
• W3213012313 isParatext "false" @default.
• W3213012313 isRetracted "false" @default.
• W3213012313 magId "3213012313" @default.

• next